CEVEC closes growth financing round to serve strong demand in viral vector technologies for cell and gene therapies

  • With its highly scalable Adenovirus and AAV production technologies, CEVEC provides cutting-edge manufacturing solutions for two of the most widely used gene therapy vectors
  • Funding will expand cell line development capacities for ELEVECTA® stable AAV
    producer cell lines
  • With ELEVECTA® currently being implemented in a second host cell type, an even stronger demand is expected

Cologne, Germany, July 27, 2021


Subscribe for the CEVEC Newsletter according to our Privacy Policy to receive the latest CEVEC News, including Press Releases, Conference Information and Webinar Invitations.

© CEVEC Pharmaceuticals GmbH 2020